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Abstract. Generalized arterial calcification of infancy (GACI) 
is an autosomal recessive disorder of spontaneous infantile 
arterial and periarticular calcification which is attributed to 
mutations in the ectonucleotide pyrophosphatase/phosphodi-
esterase 1 (Enpp1) gene. Whilst the bisphosphonate, etidronate, 
is currently used off-label for the treatment for GACI, recent 
studies have highlighted its detrimental effects on bone 
mineralisation. In the present study, we used the Enpp1-/- 
mouse model of GACI to examine the effects of etidronate 
treatment (100 µg/kg), on vascular and skeletal calcification. 
Micro-computed tomography (µCT) analysis revealed a 
significant decrease in trabecular bone mass, as reflected by 
the decrease in trabecular bone volume/tissue volume (BV/
TV; %), trabecular thickness, trabecular separation, trabecular 
number and pattern factor (P<0.05) in the Enpp1-/- mice in 
comparison to the wild-type (WT) mice. Mechanical testing 
revealed that in the WT mice, treatment with etidronate 
significantly improved work to fracture and increased work 
post-failure (P<0.05, in comparison to the vehicle-treated WT 
mice). This significant increase, however, was not observed in 
the Enpp1-/- mice. Treatment with etidronate had no effect on 
bone parameters in the WT mice; however, the Enpp1-/- mice 
displayed an increased structural model index (SMI; P<0.05). 
We used a recently developed 3D µCT protocol to reconstruct 
and quantify the extensive aortic calcification in Enpp1-/- mice 
in comparison to the WT mice. However, treatment with etidro-
nate did not prevent de novo calcification, and did not arrest the 
progression of established calcification of the aorta.
Introduction
Generalized arterial calcification of infancy (GACI) is an auto-
somal recessive disorder of spontaneous infantile arterial and 
periarticular calcification (1-3). This life-threatening disease 
is caused by loss-of-function mutations in the ectonucleotide 
pyrophosphatase/phosphodiesterase 1 (ENPP1) gene, a key 
regulator of biomineralisation and vascular calcification (4-8).
ENPP1 is a cell-surface glycoprotein enzyme that functions 
in synergy with the anklyosis protein (ANK) to respectively 
form and intracellularly channel inorganic pyrophosphate 
(PPi), an inhibitor of hydroxyapatite formation, from nucleo-
side triphosphates (9-12). The extracellular concentration 
of PPi is further influenced by tissue non-specific alkaline 
phosphatase (TNSALP), another cell-surface enzyme located 
on the cell membrane of osteoblasts and chondrocytes, as 
well as on the membranes of their matrix vesicles (MVs) (13). 
TNSALP exerts its effects by hydrolysing PPi reducing the 
concentration of this mineralisation inhibitor and establishing a 
phosphate (Pi)/PPi ratio permissive for the formation of hydroxy-
apatite crystals (14-17). Phosphatase, orphan 1 (PHOSPHO1) is 
another essential phosphatase, located within osteoblast- and 
chondrocyte-derived MVs with high phosphohydrolase activity 
toward phosphoethanolamine and phosphocholine (18-22), 
which contributes Pi for the initiation of skeletal mineralisation. 
Together, ENPP1, ANK, TNSALP and PHOSPHO1 control the 
Pi/PPi ratio conducive to physiological skeletal mineralisation. 
Thus, ENPP1 in GACI reduces extracellular PPi levels and 
predisposes to ectopic calcification. This was further exempli-
fied in a previous study of ours, in which we determined that 
vascular smooth muscle cells from mice deficient in Enpp1 have 
increased TNSALP levels (23).
In naturally occurring mouse models, the link between defec-
tive Enpp1 expression and altered mineralisation was initially 
demonstrated in ‘tiptoe walking’ (ttw/ttw) mice (24-28). These 
animals are homozygous for a G→T substitution resulting in the 
introduction of a stop codon in the NPP1 coding sequence. The 
subsequent truncated protein leads to the loss of a vital calcium 
binding domain and two putative glycosylation sites (25). The 
phenotype of this mouse includes the postnatal development 
of progressive ankylosing intervertebral and peripheral joint 
hyperostosis, as well as spontaneous arterial and articular 
cartilage calcification and increased vertebral cortical bone 
formation (24-28). Transgenic mice that are homozygous for a 
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disruption in exon 9 of the Enpp1 gene (Enpp1-/- mice) exhibit 
abnormalities that are almost identical to those present in ttw/
ttw mice (29). These include decreased levels of extracellular 
PPi, with phenotypic characteristics, including significant 
alterations in bone mineralisation in long bones and calvariae, 
and pathological, severe peri-spinal soft tissue and arterial 
calcification (30-32).
Effective treatment for infants and young children with 
GACI is critical as without it, 85% of patients succumb to 
the disease within 6 months of age. First used off-label in 
the treatment of Fibrodysplasia ossificans progressiva, 
the ‘first generation’ bisphosphonate, etidronate (EHDP; 
ethane-1-hydroxy-1,1-diphosphonic acid, also known as 
1-hydroxyethylidene-bisphosphonate) is an analogue of PPi and 
has also been used in the treatment of GACI. Bisphosphonates 
are potent inhibitors of osteoclast activity, and are widely used 
in clinical practice to prevent the bone loss associated with 
conditions, such as Paget's disease, metastatic bone disease and 
osteoporosis (33). The inhibitory effects of bisphosphonates on 
osteoblast function have also been demonstrated (34-37).
In 2008, a retrospective observational analysis of 55 patients 
with GACI revealed survival beyond infancy with etidronate 
therapy (38) corroborated by a recent study highlighting that 
15 out of 22 GACI survivors received etidronate (39). However, 
studies on uremic rats have suggested that the administration 
of etidronate may not be able to prevent arterial calcifica-
tion without inhibiting bone formation (40). Furthermore, a 
recent case report has highlighted the profound inhibition of 
skeletal mineralisation with paradoxical joint calcifications 
following protracted etidronate therapy in a 7-year-old boy with 
GACI (41). Taken together, these findings have led us to herein 
assess the effects of etidronate on bone architecture and arterial 
calcification in the Enpp1-/- mouse model of GACI.
Materials and methods
Animals. Enpp1-/- and wild-type (WT) mice were generated 
and maintained as previously described (1,5,29,42). Male mice 
were administered etidronate at 100 µg/kg, intraperitoneally 
twice a week from 11 to 22 weeks of age. The dosage of etidro-
nate used in this study was based on the dose reported in a 
previously study (43). Animals were administered saline as a 
placebo (vehicle treatment). All animals were weighed once a 
week. The animals were sacrificed at 22 weeks of age and the 
tissues were dissected for further analysis. All animal experi-
ments were approved by The Roslin Institute's Animal Users 
Committee and the animals were maintained in accordance 
with the UK Home Office guidelines for the care and use of 
laboratory animals (PIL number DD 60/3828).
Preparation of tissue. The aortae and tibiae were dissected as 
previously described (5). The aortae were fixed in 10% neutral 
buffered formalin (NBF) for 48 h before being transferred to 
70% ethanol. The tibiae were immediately frozen in distilled 
water pending analysis.
Micro-computed tomography (µCT) of the aortae. Prior to 
scanning, the aortae were immersed for a minimum period 
of time (10 min) in a macro-molecular iopamidol-based 
contrast agent (Niopam 300; Brako UK Ltd., High Wycombe, 
Buckinghamshire, UK) diluted 1:4 in water as previously 
described (44). To allow tissue differentiation, aortic luminae 
were filled with corn oil and the aortae were submersed in 
oil for the duration of the scan. Tissues were imaged using 
a Skyscan 1172 X-Ray Microtomograph (Bruker Daltonics, 
Brussels, Belgium). Sequential high-resolution scans were 
acquired using a rotation step of 0.3˚ with the averaging of 
3 frames at each step, applying a 0.5-mm aluminium filter, 
with an X-ray source set at 60 kV and 167 µA, and with an 
isotropic voxel size of 7 µm. The scans were reconstructed 
using NRecon (Bruker Daltonics). Noise in the reconstructed 
images was reduced by applying a median filter (radius = 1). 
The region of interest was selected to be the aortic arch, 
200  lices (1.4 mm) under the subclavian artery. Soft and calci-
fied tissue was identified by thresholding using CTAn software 
(Bruker Daltonics).
µCT of the tibiae. High-resolution scans with an isotropic 
voxel size of 5 µm were acquired with a µCT system (60 kV, 
0.5 mm aluminium filter, 0.6˚ rotation, Skyscan 1172; Bruker 
Daltonics). Scans were reconstructed using NRecon software 
(Bruker Daltonics). A 1,000-µm section of the metaphysis 
250 µm off the reference plate was taken for analysis of the 
trabecular bone. The base of the growth plate was used as 
a standard reference point. A 250-µm metaphysis section of 
the mid-diaphysis, 1,500 µm below the reference plate, was 
scanned for the analysis of cortical structure. Data were anal-
ysed with CTAn software (Bruker Daltonics). The following 
parameters were analysed using CTAn software (Bruker 
Daltonics): percentage bone volume/trabecular bone volume 
(%BV/TV), trabecular number (Tb.N; /mm), trabecular 
patten factor (Tb.Pf), bone mineral density (BMD; g/cm3), 
trabecular thickness (Tb.Th; mm), trabecular separation (Tb.
Sp) and the structure model index (SMI) were evaluated. In 
the cortical bone, %BV/TV, BMD (g/cm3), cortical thickness, 
cross-sectional area (mm2), the percentage of closed pores 
and polar moment of inertia (mm4) were evaluated.
Mechanical testing. Mechanical testing of the cortical bone 
was carried out using a Zwick materials testing machine 
(Zwick Armaturen GmbH, Ennepetal, Germany) and data were 
analysed as previously described (45). The span was fixed at 
6.0 mm. The cross-head was lowered at 1 mm/min and data were 
recorded after every 0.1 mm change in deflection. Each bone 
was tested to fracture. Failure and fracture points were identi-
fied from the load-extension curve as the point of maximum 
load and where the load rapidly decreased to zero, respectively. 
The maximum stiffness was defined as the maximum gradient 
of the rising portion of this curve, and the yield point, the point 
at which the gradient reduced to 95% of this value. Both values 
were calculated from a polynomial curve fitted to the rising 
region of the load-extension curve.
Serum marker analysis. To determine differences in bone 
formation and resorption, plasma serum was collected from 
the mice at 22 weeks of age. A sandwich ELISA P1NP 
(IDS Ltd., Boldons, UK) and a C-terminal telopoptide of 
type I collagen (CTx) ELISA kit (RatLaps™; IDS) were used 
respectively, and analyses were performed according to the 
manufacturer's instructions.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  36:  159-165,  2015 161
Statistical analysis. General linear model analysis, the Student's 
t-test, the Mann-Whitney non-parametric test and Pearson's 
correlation anlaysis were used to assess the data where appro-
priate. All data are expressed as the means ± SEM. Statistical 
analysis was performed using SPSS (IBM Software, New York, 
NY, USA). A value of P<0.05 was considered to indicate a 
statistically significant difference.
Results
Enpp1-/- mouse growth phenotype. In initial experiments, we 
examined whether the treatment of Enpp1-/- and WT mice 
with 100 µg/kg etidronate affects their growth. In accordance 
with our previous study, the Enpp1-/- mice exhibited a reduced 
growth in comparison to the WT mice (18.4% smaller than the 
age-matched WT controls; P<0.05) (5). Intraperitoneal injec-
tions of etidronate had no effect on the total body weight of the 
WT mice, nor the Enpp1-/- mice in comparison to the respec-
tive vehicle-treated mice (Fig. 1). Notably, the Enpp1-/- mice 
appeared to lose weight from approximately 12 weeks of age, 
which may be a consequence of their limited movement due to 
excessive joint calcification (Fig. 1) (1,5).
Aortic calcification. We have previously demonstrated that 
Enpp1-/- mice exhibit arterial calcification from 11 weeks of 
age (31). In this study, we employed our recently developed 
three-dimensional (3D) µCT protocol (44) for the quantification 
of aortic calcification to examine the effects of treatment with 
etidronate on mice lacking Enpp1. As expected, the Enpp1-/- 
mice exhibited extensive aortic calcification in comparison to 
the WT mice at 22 weeks of age (Fig. 2B). However, treatment 
with etidronate did not prevent de novo calcification, and did 
not arrest the progression of established calcification of the 
aorta in these mice (Fig. 2). 
µCT analysis of bone microarchitecture. Enpp1-/- mice have 
previously been reported to display reduced mineral content in 
bone, with a reduction in bone volume fraction and trabecular 
thickness (5). The present study extended these observations by 
fully examining the effects of the administration of etidronate 
on the bone phenotype of Enpp1-/- mice. µCT analysis of the 
tibiae from Enpp1-/- mice in comparison to those from WT mice 
(both vehicle-treated) at 22 weeks of age revealed a significant 
decrease in trabecular bone mass, as reflected by a decrease in 
%BV/TV, trabecular thickness and trabecular number (P<0.05; 
Table I). Moreover, we observed a significant decrease in 
cortical parameters in the tibiae of the 22-week-old Enpp1-/- 
Figure 2. (A) Quantification (% of calcification) of calcium deposition in the aortae of 22-week-old Enpp1-/- mice. A standardised region of calcium deposition 
(400 slices from the subclavian artery) was selected and revealed no significant differences between the placebo (vehicle; saline)- and etidronate-treated groups. 
(B) Three-dimensional volumetric reconstructions of aortae from 22-week-old wild-type (WT) placebo-treated, WT etidronate-treated, Enpp1-/-  placebo-
treated, and Enpp1-/- etidronate-treated mice. Calcification is indicated by brown colouring. Bar represents 0.5 mm.
Figure 1. Body weight of 11-week-old male Enpp1-/- and wild-type (WT) mice 
taken for 60 days from the day of administration of etidronate (day 0). Data are 
expressed as the means ± SEM.
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mice in comparison to the age-matched WT mice, except for 
cortical porosity (P<0.05; Table II). Treatment with etidronate 
had no significant effect on cortical or trabecular bone param-
eters in the WT mice (Tables I and II). In the Enpp1-/- mice, 
treatment with etidronate resulted in an increase in trabecular 
number and %BV/TV, as reflected by the significant decrease 
in trabecular separation (P<0.05, in comparison to the vehicle-
treated Enpp1-/- mice) (Table I). The Enpp1-/- mice treated with 
etidronate did show a significant decrease in SMI [quantifica-
tion of the plate- or rod-like geometry of trabecular structures, 
as previously described (46)] compared to the vehicle-treated 
Enpp1-/- mice (P<0.05; Table I).
Mechanical testing. The changes in bone geometry observed 
as a result of treatment with etidronate in the Enpp1-/- mice 
are likely to alter the biomechanical properties of long bones. 
In order to examine this hypothesis, we carried out 3-point 
bending analysis of the tibiae. Mechanical testing revealed a 
significant decrease in all mechanical parameters examined 
(stiffness, load at failure, work to failure, load at fracture, 
work to fracture, and yield) except work post-failure, in 
the Enpp1-/- mice compared to the WT mice at 22 weeks of 
age (Table III; P<0.05), reflecting reduced bone strength and 
stiffness as we have previously reported (5). In the WT mice, 
treatment with 100 µg/kg etidronate significantly improved 
work to fracture and increased work post-failure (Table III; 
P<0.05, in comparison to the vehicle-treated WT mice); 
this suggests that more energy is required to fracture these 
etidronate-treated bones in comparison to the vehicle-treated 
bones. This significant increase, however, was not observed in 
the Enpp1-/-mice treated with etidronate (Table III).
Plasma biochemical markers. The level of osteoblast and 
osteoclast activity was assessed by ELISA of serum taken from 
the etidronate-treated and vehicle-treated 22-week-old male 
Enpp1-/- and WT mice. The plasma concentrations of P1NP, a 
marker of bone formation, were unaltered in the Enpp1-/- and 
WT mice at 22 weeks of age (Fig. 3A). Moreover, no significant 
differences in bone formation were observed upon the admin-
istration of etidronate in the WT or Enpp1-/- mice (Fig. 3A). The 
plasma concentrations of CTx, a marker of bone resorption, were 
increased in the Enpp1-/- mice in comparison to the WT mice in 
Table II. µCT analysis of cortical bone in male placebo (vehicle)- and etidronate-treated Enpp1-/- and WT mice.
 WT Enpp1-/- -------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
 Placebo Etidronate Placebo Etidronate
Co.BMD (g/cm3) 1.18±0.018 1.18±0.020 1.20±0.024 1.20±0.011a
Co.Po (%) 53.27±7.26 54.79±5.64 61.75±3.71a,c 63.11±4.85a,c
Co.Th (µm) 197.90±1.91 195.64±3.84 175.98±5.96a,d 169.86±15.92a,d
Co.Area (µm2) 5.14E+06±5.57E+05 5.09E+06±3.72E+05 4.47E+06±4.2E+05a,e 4.17E+06±4.3E+05a,e
Results are expressed as the means ± SEM. aSignificant difference compared to wild-type (WT) mice; bsignificant difference compared to 
placebo-treated mice. cP<0.05; dP<0.01; eP<0.001. µCT, micro-computed tomography; cortical bone mineral density; Co.BMD, cortical bone 
mineral density; Co.Po; cortical porosity; Co.Th, cortical thickness; Co.Area, cortical area.
Table I. µCT analysis of trabecular bone in male placebo (vehicle)- and etidronate-treated Enpp1-/- and WT mice.
 WT Enpp1-/- ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
 Placebo Etidronate Placebo Etidronate
BV/TV (%) 8.79±1.59 8.75±1.79 3.39±1.06a,e 4.63±1.57a,e
BMD (g/cm3) 0.139±0.021 0.13±0.024 0.042±0.020a,e 0.062±0.025a,e
Tb.Th (µm) 60.62±4.31 57.34±8.34 48.35±3.08a,e 47.99±3.54a,d
Tb.Sp (µm) 298.24±12.68 290.47±26.56 363.66±48.07a,d 319.66±48.44b,c
Tb.N 0.00146±0.00023 0.0015±0.00029 0.00070±0.00024a,e 0.00097±0.00034a,e
Tb.Pf 0.027±0.0026 0.026±0.0033 0.042±0.0036a,e 0.0392±0.0053a,e
SMI 2.48±0.11 2.33±0.23 2.78±0.093a,d 2.69±0.22a,e
DA 2.30±0.19 2.08±0.15 2.42±0.28 2.39±0.31a,c
Results are expressed as the means ± SEM. aSignificant difference compared to wild-type (WT) mice; bsignificant difference compared to 
placebo-treated mice. cP<0.05; dP<0.01; eP<0.001. µCT, micro-computed tomography; BV/TV, bone volume/trabecular bone volume; BMD, 
bone mineral density; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Tb.N, trabecular number; Tb.Pf, trabecular patten factor; SMI, 
structure model index; DA, degree of anisotropy.
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both the etidronate- and vehicle-treated mice (P<0.05; Fig. 3B). 
This is in concordance with our previous observation of this 
marker in Enpp1-/- mice (5). However, there were no significant 
differences observed between the etidronate- and vehicle-
treated mice in either parameter (Fig. 3).
Discussion
Studies have associated treatment with bisphosphonates, chiefly 
etidronate, with improved survival in patients with GACI, an 
autosomal recessive disorder of spontaneous infantile arterial 
and periarticular calcification which is attributed to mutations 
in the ENPP1 gene (38). Animal models have proven to be 
key to the understanding of pathological ectopic mineralisa-
tion (4,47). In particular, the Enpp1-/- mouse is of particular 
importance in advancing our understanding of GACI. Thus, 
the present study was undertaken to determine the effects of 
etidronate on Enpp1-/- mice.
Our data confirm and extend those of our previous study (5), 
demonstrating that tibiae from Enpp1-/- mice have a reduced 
trabecular bone mass and cortical thickness in comparison to 
WT mice, which explains the altered bone mechanical proper-
ties noted in the present study. This, therefore, is consistent 
with the depletion of NPP1 activity reducing extracellular 
PPi to abnormally low levels, resulting in insufficient PPi a 
substrate for TNAP to generate Pi for normal mineral forma-
tion. In the present study, we also used our novel 3D µCT 
protocol to provide evidence of the severe hypermineralisation 
of the arteries in Enpp1-/- mice, consistent with reduced extra-
cellular PPi levels predisposing the vascular system to ectopic 
calcification.
Bisphosphonates are typically prescribed for the treatment 
of osteoporosis and to reduce fracture risk, preventing bone loss 
primarily by the inhibition of osteoclast function (33). However, 
there is evidence to suggest that bisphosphonates impair 
the anabolic response of bone to parathyroid hormone (48), 
inhibiting osteoblast function and suppressing bone forma-
tion (34-37). Furthermore, the hydrolysis-resistant P-C-P motif 
of bisphosphonates resembles the TNSALP susceptible core of 
PPi, (49) permitting bisphosphonates to impair calcium phos-
phate crystallisation (50). First used off-label in the treatment 
of Fibrodysplasia ossificans progressiva, the ‘first generation’ 
bisphosphonate, etidronate, is an analogue of PPi, and whilst 
it is currently being investigated as a treatment for GACI, a 
number of studies have highlighted a number of detrimental 
effects with this approach, including the development of rickets 
or osteomalacia during the protracted administration of etidro-
nate (40,41,51-56).
In this study, to clarify the effects of bisphosphonates on 
GACI, we treated WT and Enpp1-/- mice with 100 µg/kg etidro-
nate. In the WT mice, treatment with etidronate had no effect 
on cortical or trabecular parameters as determined by µCT 
analysis. Despite this, treatment with etidronate significantly 
improved work to fracture and increased work post-failure, thus 
suggesting that more energy is required to fracture these bones 
in comparison to the vehicle-treated bones. The assessment 
of bone architecture in Enpp1-/- mice treated with etidronate 
revealed a significant decrease in SMI, a method for the 
determination of the plate- or rod-like geometry of trabecular 
structures. This change in bone geometry did not, however, 
Figure 3. Serum marker analysis in Enpp1-/- and wild-type (WT) mice. 
(A) P1NP, a marker of bone formation; (B) CTx (RatLaps™), a marker of bone 
resorption. Results are expressed as the means ± SEM. *P<0.05; **P<0.01.
Table III. Measurements of tibia mechanical properties in male placebo (vehicle)- and etidronate-treated Enpp1-/- and WT mice.
 WT Enpp1-/- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------
 Placebo Etidronate Placebo Etidronate
Stiffness (N/mm) 44.56±7.08 48.82±23.43 22.42±7.19a,d 22.52±6.64a,e
Load at failure (N) 17.22±2.90 15.34±4.13 9.21±1.38a,e 8.89±1.84a,e
Work to failure (J) 0.0066±0.00066 0.0064±0.0019 0.0033±0.00081a,e 0.0035±0.00092a,e
Load at fracture (N) 1.72±0.29 1.53±0.41 0.92±0.14a,e 0.89±0.18a,e
Work to fracture (J) 0.0069±0.00087 0.0086±0.0019b,c 0.0038±0.0011a,e 0.0044±0.00082a,e
Work post-failure (J) 0.00037±0.00041 0.0023±0.0014b,d 0.00055±0.00082 0.00088±0.0012a,c
Yield (N) 14.41±3.95 12.97±4.42 6.96±1.45a,e 7.11±1.79a,d
Results are expressed as the means ± SEM. aSignificant difference compared to wild-type (WT) mice bsignificant difference compared to 
placebo-treated mice; cP<0.05; dP<0.01; eP<0.001.
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affect the bone mechanical properties. Consistent with this, the 
assessment of plasma markers of bone formation and resorp-
tion revealed that this dosage of etidronate did not significantly 
affect the bone remodelling process in the Enpp1-/- mice, nor 
in WT mice. These findings add further support to those of a 
recent in vivo study using mice, which also reported no effects 
of the administration of etidronate on bone resorption (57). 
Furthermore, the anti-resorptive effects of alendronate, risedro-
nate and minodronate were revealed to be 1,000-, 3,300- and 
10,000-fold greater than those of etidronate, respectively (57).
Surprisingly, and in contrast to previous data on rats with 
experimental renal failure (40), treatment with etidronate did 
not prevent de novo calcification, and did not arrest the progres-
sion of established calcification of the aorta in our Enpp1-/- mice. 
Taken together, these data suggest that the skeleton here is 
displaying an expected response to etidronate treatment, but 
this is not yet toxic to aortic calcification. 
The mild effects of etidronate observed in this study may be 
explained by the dosage used, the frequency of administration 
and/or species differences. Future studies may aim to investi-
gate a higher dosage and/or daily administration of etidronate, 
as previously it has been shown that high doses of etidronate 
significantly reduce mineralisation (58). Furthermore, in the 
present study, treatment of the mice commenced when the 
mice were 11 weeks of age, the point at which calcification is 
observed in this model (5). However, this initiation of treatment 
may have been too late to resolve underlying, pre-existing 
calcifications and additional investigation into this would allow 
further conclusions to be drawn.
In conclusion, despite the changes in bone microarchitec-
ture, we did not observe an inhibition of aortic calcification or 
bone formation in the Enpp1-/- mice treated with etidronate. 
Additional studies are, therefore, required to fully determine 
whether etidronate is the most appropriate therapy for the 
treatment of GACI.
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